Shares of Johnson & Johnson (NYSE: JNJ) closed the latest trading session at $269.12, down 2.22% from the previous close. The decline was steeper than the broader market’s performance, with the S&P 500 falling 0.58%, the Dow Jones Industrial Average declining 1.18%, and the tech-heavy Nasdaq Composite losing 0.32%.

Despite the latest pullback, J&J shares had delivered stronger recent performance. Before the latest session, the healthcare giant’s stock had advanced 5.13%, outperforming the Medical sector, which gained 2.73%, while the S&P 500 had declined 0.36% over the same period.

Earnings Report in Focus

Investors are now turning their attention to Johnson & Johnson’s upcoming earnings release, scheduled for October 13, 2026. Analysts expect the company to report earnings per share (EPS) of $2.95, representing a 5.36% increase from the same quarter a year earlier.

Revenue is projected at approximately $25.36 billion, marking an estimated 5.71% year-over-year increase. For the full fiscal year, Zacks Consensus Estimates call for earnings of $11.59 per share and revenue of $101.09 billion, reflecting annual growth of 7.41% and 7.32%, respectively.

Analyst Estimates Offer Key Signal

Changes in analysts’ earnings estimates remain an important indicator for investors, as upward or downward revisions can reflect shifting expectations around a company’s near-term operating performance and profitability.

Over the past 30 days, the Zacks Consensus EPS estimate for Johnson & Johnson has edged 0.03% lower. The company currently carries a Zacks Rank of #3 (Hold).

The Zacks Rank ranges from #1 (Strong Buy) to #5 (Strong Sell) and is based partly on earnings estimate revisions, which Zacks says have historically been linked to near-term stock-price momentum.

Valuation Remains Elevated

Johnson & Johnson currently trades at a forward price-to-earnings (P/E) ratio of 23.75, above the industry average of 17.92. Its PEG ratio, which factors expected earnings growth into valuation, stands at 2.63, compared with an average of 2.27 for large-cap pharmaceutical stocks. The premium valuation suggests investors continue to place a relatively strong value on J&J’s earnings prospects, even as the stock faces near-term market pressure.

Also Read :- Johnson & Johnson Proposes Up to $5.5 Billion Settlement to Resolve US Talc Lawsuits